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Summary
Ehlers-Danlos syndrome (EDS) is a heterogeneous group
of connective-tissue disorders characterized by skin fra-
gility, joint laxity, and skeletal deformities. Type V col-
lagen appears to have a causal role in EDS types I and
II, which show phenotypic overlap and may sometimes
be allelic. Type V collagen can exist as a heterotrimer,
[a1(V)]2a2(V), and it both coassembles with and regu-
lates type I collagen–fibril diameter. Using an intragenic
COL5A1 polymorphism, we have demonstrated linkage,
at zero recombination, to the same allele in two large
British EDS type II families (LOD scores 4.1 and 4.3).
Affected members from each family were heterozygous
for a point mutation in intron 32 (IVS32:T-25G), caus-
ing the 45-bp exon 33 to be lost from the mRNA in
∼60% of transcripts from the mutant gene. This mu-
tation lies only 2 bp upstream of a highly conserved
adenosine in the consensus branch-site sequence, which
is required for lariat formation. Although both families
shared the same marker allele, we have been unable to
identify a common genealogy. This is the first description
of a mutation at the lariat branch site, which plays a
pivotal role in the splicing mechanism, in a collagen
gene. Very probably, the resulting in-frame exon skip
has a dominant-negative effect due to incorporation of
the mutant proa chain into the triple-helical molecule.
These findings further confirm the importance of type
V collagen in the causation of EDS type II, and the novel
collagen mutation indicates the importance of the lariat
branch site in splicing.
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Introduction
At least nine clinical subtypes of Ehlers-Danlos syn-
drome (EDS) are recognized in the Berlin nosology
(Beighton et al. 1988). The cardinal manifestations in-
clude cutaneous fragility, hyperextensibility, and liga-
mentous laxity, with occasional skeletal deformities and
rupture of hollow organs. All molecular defects in EDS
described to date result in abnormalities of the fibrillar
collagens (Pope and Burrows 1997). EDS types I (MIM
130000) and II (MIM 130010) show autosomal dom-
inant inheritance, and patients are characterized by
atrophic scars, cutaneous hyperextensibility, and joint
laxity. EDS type II is less severe than EDS type I, with
less propensity to internal organ involvement and pre-
mature rupture of fetal membranes. Reported linkage to
the COL5A1 gene, which encodes for the a1 chain of
type V collagen, in a family with EDS type I and in a
mixed-EDS type I/II family, was the first evidence that
these disorders can be allelic (Loughlin et al. 1995; Bur-
rows et al. 1996).
Type V collagen is distributed ubiquitously in humans.
It coassembles with and regulates fibrillogenesis of type
I collagen (Birk et al. 1990; Linsenmayer et al. 1993;
Fichard et al. 1995). Type V collagen usually exists as
a heterotrimer of proa1(V) and proa2(V) chains, en-
coded by COL5A1 (Greenspan et al. 1992) and
COL5A2 (Emanuel et al. 1985), respectively. A third
chain (proa3[V]) exists (Sage and Bornstein 1979), al-
though the COL5A3 gene has not been identified.
A role for type V collagen in EDS was suggested by
the identification of an exon-skipping mutation in
COL5A1 in a patient with sporadic EDS type II (Nicholls
et al. 1994). The presence of short stature and foot ab-
normalities were also consistent with EDS type VII, but
collagen fibril structure, protein chemistry, and DNA
analysis excluded this possibility (Nicholls et al. 1996).
Several COL5A1 mutations have now been reported,
including a translocation through intron 24 in a sporadic
EDS type I patient with hypomelanosis of Ito (Toriello
et al. 1996), abnormal splicing affecting the C-propep-
tide in both an EDS type I family (Wenstrup et al. 1996)
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Figure 1 Cosegregation of an intragenic COL5A1 marker with EDS type II phenotype in two families: MK family (A) and CH family
(B). Blackened symbols indicate affected individuals; unblackened symbols indicate unaffected individuals. Allele frequency and size are from
Greenspan et al. (1995): 1 (9%, 182 bp); 2 (6%, 188 bp); 4 (69%, 192 bp); 5 (14%, 194 bp); and 6 (1%, 198 bp).
and an EDS type II family (de Paepe et al. 1997), and
a cysteine substitution in the C-propeptide in EDS type
I (de Paepe et al. 1997). Here we describe a unique
collagen mutation of the lariat branch site of COL5A1,
resulting in abnormal splicing of exon 33, in two British
families.
Material and Methods
This study was approved by the local ethical com-
mittee.
Electron Microscopy
Skin biopsy samples were taken, under local anes-
thetic, from the inner part of the upper arm. One cubic
millimeter was processed for electron microscopy as de-
scribed elsewhere (Nicholls et al. 1996), and the re-
mainder was used for fibroblast culture.
Linkage Analysis
Eleven affected members of the MK pedigree and eight
members of the CH pedigree were examined by one of
us (N.P.B.). All fulfilled the clinical criteria for EDS type
II—namely, atrophic scarring confined to elbows and
knees, evidence or history of easy bruising, joint laxity,
and moderate cutaneous hyperextensibility. Leukocyte
DNA was extracted from 10 ml peripheral blood by
means of a Nucleon II kit (Scotlab), in accordance with
the manufacturer’s instructions. Genotype studies were
performed after PCR of a polymorphic simple-sequence
repeat (SSR) within intron 17 of COL5A1, as described
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Figure 2 Transmission-electron micrography. Transversely sec-
tioned upper dermal collagen from (a) an EDS type II family member
(V.5, CH family), showing considerable variation in both size and
shape of collagen fibrils (several “cauliflower” fibrils are present), and
from (b) a clinically unaffected individual from MK family, as a control
(IV.8). (Bar  0.5mm)
Figure 3 cDNA amplification. A, COL5A1 RT-PCR products
(2822–3163 bp) from cultured dermal fibroblasts. Affected individual
III.12 (MK family) is heterozygous for the deleted product. C  con-
trol; L  ladder. B, Autoradiograph of a denaturing polyacrylamide
gel of RT-PCR products of patients III.12 (MK family) and V.5 (CH
family), using a [33P] end-labeled primer for a limited number of cycles.
The film was analyzed by densitometry to obtain the relative amounts
of normal and deleted transcript species.
elsewhere by Greenspan et al. (1995). Each reaction was
performed in 12.5 ml containing a forward primer end-
labeled with g[33P]-ATP and T4 polynucleotide kinase,
as described elsewhere (Burrows et al. 1996). Alleles
were separated by electrophoresis in a 6% denaturing
polyacrylamide gel and were visualized by autoradiog-
raphy. LOD scores were calculated with the LIPED com-
puter program (Ott 1974), under the assumption of an
autosomal dominant disease with a gene frequency of
0.1% and equal male and female recombination frac-
tions. Allele frequencies for the COL5A1 marker were
those reported by Greenspan et al. (1995). Three pol-
ymorphic markers (CA repeats)—D9S298, D9S114,
and D9S1818, which lie in close proximity to
COL5A1—were labeled as above. The markers were
used for comparison of more-detailed haplotype status
of two affected individuals from both families.
cDNA Amplification
Total cytoplasmic RNA was obtained from cultured
dermal fibroblasts from at least two affected individuals
from both families and was used to reverse transcribe
cDNA. Using the cDNA sequence (GenBank, accession
number M76729) described by Greenspan et al. (1991)
and Takahara et al. (1995), we amplified the cDNA in
17 overlapping fragments of ∼300–500 bp in length, to
cover the entire open reading frame, as follows: product
1, bases 344–624; product 2, bases 482–924; product
3, bases 854–1287; product 4, bases 1129–1560; prod-
uct 5, bases 1367–1776; product 6, bases 1679–2067;
product 7, bases 1999–2500; product 8, bases 2442–
2877; product 9, bases 2822–3163; product 10, bases
3026–3437; product 11, bases 3382–3862; product 12,
bases 3757–4177; product 13, bases 4085–4435; prod-
uct 14, bases 4386–4786; product 15, bases 4726–5201;
product 16, bases 5050–5556; and product 17, bases
5342–5803. (Numbers refer to nucleotide positions of
the 5′ base of the 20-mer primers.) A reverse primer in
exon 33 (bases 2936–2956) was used with a forward
primer (bases 854–874) to selectively amplify the non-
deleted message. This 2.1-kb fragment was gel purified
and reamplified with the same forward and the 1287
reverse primer prior to restriction-enzyme analysis with
PstI. Products were electrophoresed in a 4% polyacryl-
amide gel, stained with ethidium bromide, and visualized
under uv light.
Quantitative PCR of fragment 9 was performed by
use of a [33P] end-labeled primer (base 3163) for 25
cycles. The product was denatured, run on a 4% de-
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Figure 4 cDNA sequence analysis of sense strand of cloned cDNA showing loss of exon 33 in an affected individual, III.12 (MK family).
The nucleotide, amino acid sequences, and exon boundaries are shown. The first glycine of the triple helix has been assigned as number “1.”
naturing polyacrylamide gel, and visualized by autora-
diography. The band intensities were determined by den-
sitometry, and the ratio of the two transcripts was
calculated.
cDNA Sequencing
The normal and shortened cDNA products were sep-
arated by electrophoresis in a 2% agarose gel, excised,
and eluted in water by means of the Qiaquick gel-elution
kit (Qiagen). The cDNAs were made blunt ended with
the Klenow fragment of DNA polymerase, phosphoryl-
ated with T4 polynucleotide kinase, and then cloned into
pBluescript plasmids, in accordance with the manufac-
turer’s instructions (Stratagene). Individual clones were
sequenced by use of Sequenase version 2.0 T7 poly-
merase (U.S. Biochemical) and vector-specific primers,
analyzed by electrophoresis in a 6% denaturing poly-
acrylamide gel, and autoradiographed.
Genomic DNA Analysis
Amplification and sequencing were initially performed
to analyze the intron 32 acceptor splice site, exon 33,
intron 33, and part of exon 34. The sequence was nor-
mal, and, therefore, long-range PCR amplification was
performed between exon 32 and exon 34 (∼6 kb), by
use of Taqplus (Stratagene). Using sequence obtained
from this DNA fragment, we designed a forward primer
(5′ tgc tct gaa ttc aca gtc tct caa 3′) ∼100 bp upstream
of the intron 32/exon 33 boundary. This was used with
a reverse primer in exon 34 (5′ agt gat gcc ccg ggg gcc
tct ttc 3′), for amplification and sequencing reactions.
This product was directly sequenced in both directions
by means of a Thermo Sequenase cycle sequencing kit
(Amersham Life Sciences), and the mutation was iden-
tified in both strands. The mutation created an AlwI
restriction-enzyme site. Genomic DNA from all family
members of both pedigrees, 30 normal individuals, and
23 unrelated EDS type I and EDS type II patients was
amplified, incubated with AlwI restriction enzyme at
37C overnight, and electrophoresed in 4% polyacryl-
amide gel prior to being stained with ethidium bromide.
Results
Clinical Findings
Two five-generation British families exhibited similar
phenotypes characteristic of EDS type II. All affected
individuals demonstrated soft, moderately hyperexten-
sible skin, with scarring confined to elbows and knees,
and a variable degree of joint hypermobility. In addition,
affected family members had histories of mild to mod-
erate bruising after trauma. There were no varicose veins
or skeletal deformities, and there was no history of in-
ternal organ involvement or premature births. Individ-
uals III.8 (MK family) and V.4 (CH family) demon-
strated extreme joint laxity (Beighton scores [Beighton
et al. 1973] 7/9 and 9/9, respectively) but no cutaneous
involvement. These features were consistent with benign
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Figure 5 PstI-digestion gel. Ethidium bromide–stained poly-
acrylamide gel of PstI digests of cDNA PCR amplified specifically from
the normal-sized RNA of individual III.12 (MK family) and (C) control
(/) cDNA. The plus signs () and minus signs () above lanes
indicate whether enzyme was added to the reaction mix.
hypermobile syndrome, and the individuals were, there-
fore, scored as unaffected.
Ultrastructural Studies
Skin biopsy samples were taken from individuals
III.12, III.13, IV.7, IV.8, and IV.9 (MK family) (fig. 1A)
and from individuals IV.1 and V.5 (CH family) (fig. 1B),
for dermal fibroblast culture and electron microscopy.
Ultrastructural analysis of collagen fibrils in affected in-
dividuals consistently showed wide variation in size and
shape, in transverse sections (fig. 2a). Numerous “cau-
liflower” fibers were present in three biopsy samples.
These features were absent in the biopsy sample from
an unaffected individual (IV.8, MK family) (fig. 2b).
Molecular Studies
Genomic DNA was obtained from peripheral blood
mononuclear cells of affected and relevant unaffected
individuals. Analysis of a COL5A1 SSR revealed that
allele 1 (frequency 9%, size 182 bp) consistently cose-
gregated with the EDS type II phenotype, without re-
combination (fig. 1A and B). The maximum LOD scores
for the MK and CH families were 4.1 and 4.3, respec-
tively, at a recombination fraction of zero, providing
significant evidence of linkage of COL5A1 to the EDS
type II phenotype. Affected individuals from both fam-
ilies shared a common allele for three polymorphic
markers at 9q34 (data not shown).
Mutational analysis of COL5A1 cDNA was per-
formed by use of 17 overlapping reverse transcrip-
tion–PCR (RT-PCR) products from RNA extracted from
cultured dermal fibroblasts. PAGE showed both a nor-
mal and a smaller-length product in one fragment (bp
2822–3163) (fig. 3A). After denaturation, the deleted
product represented ∼30% of the total transcript (fig.
3B). Cloning and sequencing of the normal and mutant
products detected a 45-bp deletion corresponding to
exon 33 (fig. 4), which encoded part of the collagen helix
(Takahara et al. 1995). After specific amplification of
the nondeleted fragment, PstI restriction-enzyme diges-
tion revealed that the cDNA product was heterozygous
for this polymorphism, thereby confirming the presence
of alternative splicing (fig. 5).
Initial amplification and extensive sequencing of the
acceptor splice site at the 3′ end of intron 32, exon 33,
intron 33, and part of exon 34 showed the normal se-
quence. To further analyze the sequence of the 3′ end of
intron 32, a 6-kb region, from exon 32 to exon 34, was
amplified and partially sequenced. This sequence was
used to generate additional primers, which were used to
amplify genomic DNA and which showed a TrG point
mutation within the branch-site sequence in intron 32
(IVS32:T-25G), 2 bp upstream of the highly conserved
adenosine (fig. 6A and B). This base change created an
AlwI restriction-enzyme site. PCR products of normal
genomic DNA did not contain an AlwI restriction-en-
zyme site, but the presence of the mutation in the PCR
product yielded two fragments, of ∼230 bp and ∼80 bp
(fig. 7). Digestion of amplified genomic DNA from all
available family members confirmed that the mutation
cosegregated consistently with disease, in both families,
but was absent in 30 normal individuals and in 23 un-
related EDS type I and EDS type II patients (data not
shown).
Discussion
There is convincing evidence that the COL5A1 trans-
version described above causes EDS type II. First, linkage
to COL5A1 is present in both families. Second, the mu-
tation as detected by AlwI restriction-enzyme digestion
also segregated with the disease phenotype in these fam-
ilies but was absent both from healthy individuals and
from other unrelated EDS type I and EDS type II pa-
tients. It was therefore unique to these affected families
and is not a polymorphism. Third, other COL5A1 mu-
tations occur in EDS types I and II (Nicholls et al. 1996;
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Figure 6 A, Genomic DNA sequence analysis, from the junction of intron 32/exon 33, in an EDS type II member from each family (IV.1,
CH family, and III.12, MK family) and in a control (normal) individual. The heterozygous T/G base is shown in the affected individuals. B,
Schematic diagram of mutation. The position of the COL5A1 mutation (IVS32:T-25G) is within the putative branch site. Uppercase letters
indicate exon nucleotides; lowercase letters indicate intron nucleotides. The invariant nucleotide of the branch site is underlined, and the mutation
is bracketed.
Toriello et al. 1996; Wenstrup et al. 1996; de Paepe et
al. 1997), although there have been no reports of a
branchpoint mutation, nor are there any previous re-
ports of collagen gene mutations involving this site.
The branch-site consensus region is 6–59 nucleotides
upstream of the 3′ splice site (Maquat 1996) and has a
weak consensus sequence, Y81 NY100 T87 R81 A100
Y94 (Y  pyrimidine; R  purine; N  any base; and
numbers represent percentages) (Krainer and Maniatis
1988). We assigned the lariat branch site by identifying
the first adenosine 23 bases upstream of the acceptor
splice site to be surrounded by sequence homologous to
that of the consensus eukaryotic lariat branch site. Aden-
osine is the single most important nucleotide of branch-
ing function and is usually flanked by the sequence UAC-
UAAC, which is the most efficient for mammalian
mRNA splicing (Zhuang et al. 1989). It is also the site
for binding of the U2 small nuclear ribonuclear protein
complex (Reed and Maniatis 1988; Wu and Manley
1989; Query et al. 1994). The mutation in the families
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Figure 7 Restriction-enzyme–digestion analysis of genomic
DNA from part of the CH family. The same PCR fragment used for
genomic sequence analysis was digested with AlwI. The products were
analyzed by 4% PAGE, along with a 1-kb ladder (L). The extra bands
present in the digested DNA from affected individuals are indicated
by the arrows.
reported here lies only 2 bp upstream of the highly con-
served adenosine. Kuivenhoven et al. (1996) reported a
similar branch-site point mutation (IVS4:T-22C) in the
lecithin:cholesterol acyltransferase gene, in a family with
fish-eye disease, a condition characterized by corneal
opacities and low plasma HDL cholesterol. The muta-
tion caused intron retention rather than the exon skip-
ping that occurred in the families we report here. Kuiv-
enhoven et al. (1996) postulated that this occurred
because of interference of U2 snRNP binding to pre-
mRNA, with failure of correct conformational bulging
of the branchpoint adenosine residue essential for the
normal branching reaction (Query et al. 1994; Kuiv-
enhoven et al. 1996). Reed and Maniatis (1988) have
shown that a UrA base change at the fourth position
of the branch site (2 bp upstream of the conserved aden-
osine) severely reduces splicing efficiency in vitro. Their
mutation caused preferential splicing with the normal
branch site and 3′ splice site of the downstream intron.
In the families reported here, because intron 33 is rel-
atively small (135 bp), its internal branch site could be
preferred to the mutated site in intron 32. Consequently,
there is “looping out” and loss of the COL5A1 exon
33, which is included in the lariat product. The fact that
the deleted product was ∼30% of the total suggested
that the mutation was allowing alternative splicing of
exon 33. To investigate this possibility, we tested several
coding-sequence polymorphisms identified during this
work, and we found individual III.12 (MK family) to be
heterozygous for a PstI polymorphism (at base 967). By
specific amplification of the nondeleted cDNA product,
we showed that products from both alleles were present,
confirming alternative splicing.
Biochemical analyses of collagen synthesized by cul-
tured dermal fibroblasts from affected individuals did
not detect any abnormal type V collagen (data not
shown). Likewise, de Paepe et al. (1997) previously re-
ported normal migration patterns for type V collagen,
despite the presence of abnormally spliced COL5A1
transcripts. However, skipping of exon 33 still leaves the
mRNA in-frame but will shorten the helical region of
the proa1(V) chain by 15 amino acids. The mutant can
still associate with the other proa(V) chains through the
functional C-propeptide and thereby can act as a dom-
inant-negative mutation (Marchant et al 1996). We have
been unable to determine whether the phenotype is due
to decreased amounts of type V collagen, the presence
of the mutant molecule, or both.
Type V collagen is found in a large number of diverse
tissues, including skin, fetal membranes, bone, cartilage,
cornea, and blood-vessel walls. It coassembles with col-
lagen I and III in noncartilagenous tissues (Birk et al.
1990; Linsenmayer et al. 1993). Although less abundant
than the other fibrillar collagens, it participates in fi-
brillogenesis, with a predominantly regulatory rather
than structural function (Linsenmayer et al. 1993; An-
drikopoulos et al. 1995; Marchant et al. 1996). Dimin-
ished type V collagen levels in chick corneas cause ab-
normally large heterotypic type I/V fibrils because of loss
of regulation (Birk et al. 1990; Marchant et al. 1996).
It has been suggested that the amino-terminal domains
of type V collagen, which are located at the fibril surface,
inhibit fibril growth, by steric or electrostatic mecha-
nisms (Linsenmayer et al. 1993; Marchant et al 1996).
The ultrastructural abnormalities of dermal collagen in
biopsies from these families further support an impor-
tant regulatory role of type V collagen in matrix
assembly.
A mutation involving the branch site is rare and has
not been reported previously in any of the collagen
genes. Although both of the families we report share the
same COL5A1 marker allele, which is found in only 9%
of the population (Greenspan et al. 1995), we have been
unable to demonstrate a common genealogy. However,
using markers in close proximity to COL5A1, we de-
termined that both families shared a number of alleles,
suggesting a common founder effect. Furthermore, since
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this mutation is not present in 23 other British EDS type
I and EDS type II families, it is likely that the two families
described herein are distantly related.
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